日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial

比瑞西尼联合氟维司群治疗内分泌进展后的晚期乳腺癌:BRIGHT-2 III期随机临床试验

Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Hu, Yan; Wang, Qiuli; Duan, Xianghui; Yang, Fan; Wang, Li; Xu, Binghe

Unveiling the Th17/Treg imbalance: a key player in Clostridioides difficile-induced infection

揭示 Th17/Treg 失衡:艰难梭菌感染的关键因素

Xu, Siqi; Li, Hongsheng; Ni, Lixia; Dong, Wenjia; Xie, Aqing; Yu, Junjie; Wu, Xiaoyan; Hu, Xuqi

Preoperative assessment of axillary lymph node tumor burden in cT1-2N0 breast cancer patients with a modality-adaptive network based on sentinel lymph node ultrasound images

基于前哨淋巴结超声图像的自适应网络对cT1-2N0期乳腺癌患者腋窝淋巴结肿瘤负荷进行术前评估

Gao, Yuanjing; Gu, Difei; Li, Juan; Niu, Zihan; Liu, Rui; Luo, Yanwen; Zhou, Mengyuan; Xiao, Mengsu; Mao, Feng; Zhou, Yidong; Jiang, Yuxin; Li, Hongsheng; Lu, Man; Zhu, Qingli

Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis

Bireociclib联合氟维司群治疗HR+/HER2-晚期女性乳腺癌(内分泌治疗后进展):BRIGHT-2 III期研究中期分析

Wang, Jiayu; Zhang, Qingyuan; Li, Huiping; Tong, Zhongsheng; Ouyang, Quchang; Li, Huihui; Teng, Yuee; Wang, Biyun; Sun, Tao; Wang, Jingfen; Li, Wei; Niu, Zhaofeng; Li, Hongsheng; Gong, Chang; Wang, Shu; Wang, Xinshuai; Wu, Xinhong; Liu, Ning; Yu, Guohua; Liu, Fei; Duan, Xianghui; Wang, Shuya; Meng, Yaping; Wang, Li; Xu, Binghe

Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Capivasertib联合氟维司群治疗HR阳性/HER2阴性晚期乳腺癌患者:3期CAPItello-291研究扩展中国队列

Hu, Xichun; Zhang, Qingyuan; Sun, Tao; Xiong, Huihua; Li, Wei; Teng, Yuee; Lu, Yen-Shen; Tseng, Ling-Ming; Yan, Min; Li, Hongsheng; Pang, Danmei; -Chen, Shin-Cheh; Chen, Wenyan; Jiang, Ou; Wang, Jingfen; Wu, Xinhong; Wang, Xian; Zang, Aimin; Wang, Xiaojia; Collins, Julie M; Fan, Ethan; Jiang, Lin; Zeng, Xiaoling; Turner, Nicholas C

Granzyme B activated near-infrared-II ratiometric fluorescent nanoprobe for early detection of tumor response to immunotherapy.

颗粒酶 B 激活的近红外 II 比率荧光纳米探针用于早期检测肿瘤对免疫疗法的反应

Ding Lei, Zhang Xiaolong, Wang Peiyuan, Ke Jianmei, Zhou Yang, Wu Ming, Wei Zuwu, Cao Yanbing, Li Hongsheng, Chen Geng, Zheng Guangwei, Zeng Yongyi, Hong Maochun, Liu Xiaolong

Retraction Note to: KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation

撤稿声明:KLF5调控的lncRNA RP1通过抑制p27kip1翻译促进乳腺癌的生长和转移

Jia, Xiaoting; Shi, Lejuan; Wang, Xiaorong; Luo, Liyun; Ling, Li; Yin, Jiang; Song, Ying; Zhang, Zhijie; Qiu, Ni; Liu, Hao; Deng, Min; He, Zhimin; Li, Hongsheng; Zheng, Guopei

Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways

白细胞介素-21工程改造通过增强代谢途径来提高CD19特异性CAR-NK细胞对抗B细胞淋巴瘤的活性

Bailin He #,Hong Chen #,Jiaxu Wu,Shiqiu Qiu,Qiusui Mai,Qing Zeng,Cong Wang,Shikai Deng,Zihong Cai,Xiaoli Liu,Li Xuan,Chengyao Li,Hongsheng Zhou,Qifa Liu,Na Xu

Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer

CD8(+) T 细胞与肿瘤细胞的空间接近程度可预测乳腺癌新辅助治疗的疗效

Liang, Hongling; Huang, Jianqing; Li, Hongsheng; He, Weixing; Ao, Xiang; Xie, Zhi; Chen, Yu; Lv, Zhiyi; Zhang, Leyao; Zhong, Yanhua; Tan, Xiaojun; Han, Guodong; Zhou, Jie; Qiu, Ni; Jiang, Ming; Xia, Haoming; Zhan, Yongtao; Jiao, Lei; Ma, Jie; Radisky, Derek; Huang, Jia; Zhang, Xuchao

Ferroptosis in cancer: revealing the multifaceted functions of mitochondria

癌症中的铁死亡:揭示线粒体的多重功能

Ding, Xinyi; Cui, Lei; Mi, Yanjun; Hu, Jiachun; Cai, Zheyou; Tang, Qing; Yang, Linhao; Yang, Zhuang; Wang, Qingbing; Li, Hongsheng; Hou, Benxin; Liu, Quentin; Zou, Zhengzhi; Chen, Yibing